Editorial - Research on Chronic Diseases (2023) Volume 7, Issue 3

Herbal medicine for treatment of chronic obstructive pulmonary disease (Asthma or chronic obstructive pulmonary disease): A prospective observational study

Luneburg Nicole*

Division of Respiratory Medicine, Department of Internal Medicine, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea

*Corresponding Author:
Luneburg Nicole
Division of Respiratory Medicine, Department of Internal Medicine, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea
E-mail: lueneburg2.nicole@edu.de

Received: 01-5-2023, Manuscript No. oarcd-23-91814; Editor assigned: 03- 5-2023, Pre QC No.; Reviewed: 17-5- 2023, QC No. 91814; Revised: 23-5- 2023, Manuscript No. oarcd-23-91814 (R); Published: 30-5-2023; DOI: 10.37532/rcd.2023.7(2).033-035


Obstructive aviation route illness may be a major wellbeing issue and contains a incredible effect on worldwide financial burden. In spite of helpful propels in later decades, there’s still a require for successful and secure restorative operators for patients with asthma or constant obstructive pneumonic infection (COPD). Strategies. This imminent observational think about investigated the impacts of home grown solutions in patients with asthma and COPD. All members gone by the clinic at least every 4 weeks for 12 weeks to get their home grown medications based on their design distinguishing proof and to assess security and adequacy endpoints. We take after the symptomatic criteria utilized by Korean medication specialists to endorse home grown drugs, investigated varieties in endorsed home grown medications, and investigated a number of clinical highlights in patients with asthma or COPD. Comes about. A add up to of 24 patients were selected: 14 were analyzed with asthma and 10 with COPD and 19 completed the ponder. After 12 weeks of home grown pharmaceutical treatment, home grown drugs essentially made strides the adjusted Clinical Asthma Estimation Scale in Oriental Medicine-V in asthma patients and the altered Restorative Investigate Committee Dyspnoea Scale and St. George’s Respiratory Survey in COPD patients. For all patients, altered Restorative Inquire about Committee Dyspnoea Scale score and interleukin-13 were found to be essentially diverse after treatment. Also, the larger part of patients were fulfilled with our home grown pharmaceutical medications, and no extreme antagonistic occasions were detailed amid the ponder.


Symptomatic criteria • Korean medication • Dyspnoea scale • George’s Respiratory • Pharmaceutical medications


Chronic obstructive pulmonary disease (COPD) is a prevalent and debilitating respiratory condition characterized by persistent airflow limitation. It encompasses several respiratory disorders, including asthma, chronic bronchitis, and emphysema. COPD significantly impacts the quality of life of affected individuals and poses a considerable burden on healthcare systems worldwide [1]. While conventional medical treatments have shown efficacy in managing COPD symptoms, there is a growing interest in exploring alternative approaches, such as herbal medicine, to provide additional relief and improve overall outcomes. Herbal medicine, also known as botanical medicine or phytomedicine, involves the use of plants and their extracts to treat various ailments. Throughout history, different cultures have relied on the healing properties of herbs for respiratory conditions, including asthma and COPD. Herbal remedies offer a range of potential benefits, including anti-inflammatory, bronchodilatory, and immune-modulating effects, which may provide relief from COPD symptoms and improve lung function. However, it is essential to conduct rigorous research to assess the safety, efficacy, and potential interactions of herbal medicines before integrating them into mainstream COPD treatment protocols [2].

Our think about provides preliminary clinical information on the security and adequacy of home grown drugs in patients with asthma and COPD [3]. Asthma and persistent obstructive pneumonic infection (COPD) are the foremost predominant obstructive aviation route illnesses related with unremitting irritation and aviation route hindrance [4]. In spite of helpful progresses in later decades, both illnesses are expanding in predominance and horribleness, influencing more than 500 million individuals around the world. The worldwide predominance of asthma in grown-ups is assessed to be 4.3%, and the predominance of COPD is 11.7%. In expansion, these persistent respiratory infections have critical antagonistic impacts on quality of life, incapacity, and efficiency, in this manner expanding the social and financial burden. In this way, compelling helpful procedures for asthma and COPD are fundamental to move forward the physical and mental well-being of patients and diminish the financial burden of respiratory malady [5].

Asthma is characterized by a history of respiratory indications such as wheezing, shortness of breath, chest snugness, hack and variable wind current restriction [6]. For the current treatment for asthma, bronchodilators and antiinflammatory medicines are essentially utilized to control side effects and to diminish the hazard of asthma. In any case, as it were half of patients with asthma react enough to current treatments [7]. COPD moreover presents with side effects comparative to those of asthma, such as constant hack, overabundance sputum generation, chest snugness, and shortness of breath amid physical movement, which is more often than not caused by critical presentation to noxious particles or gasses [8]. Pharmacological treatments, counting long-acting bronchodilators and breathed in corticosteroids (ICS), are utilized to decrease the indications, recurrence, and seriousness of exacerbations, and to make strides physical exercises, in spite of the fact that there’s no conclusive prove of long-term decrease in lung work [9]. Hence, these unsuitable treatment results and antagonistic impacts from customary solutions contribute to the restorative needs for extra successful and secure restorative operators for asthma or COPD [10].


Over the past decades, complementary or elective medication (CAM), counting home grown medications, has been broadly utilized for the treatment of asthma and COPD, with small chance and few complications. A past consider detailed that 52% of patients with asthma and 33% with COPD had utilized CAM some time recently. Another US overview moreover found that sensitivities and lung issues were a few of the foremost visit therapeutic conditions where CAM had been utilized some time recently. As of late, a few orderly audits have been conducted to decide the adequacy of these home grown drugs and found the potential viability of home grown solutions in both asthma and COPD with useful anti-inflammatory, antioxidant, immunostimulatory, antimicrobial, hack suppressant, smooth muscle relaxant, and expectorant impacts. In any case, the viability of CAM remains uncertain due to the moo quality of considers, and assist ponders are required to distinguish novel helpful home grown drugs for asthma and COPD.

Healthcare professionals should engage in open and informed discussions with patients about the use of herbal medicine, ensuring that potential risks, benefits, and limitations are thoroughly understood. Furthermore, standardized guidelines and regulations for herbal medicine use need to be developed to ensure quality control, minimize interactions with conventional medications, and safeguard patient health.

By expanding our understanding of herbal medicine’s role in COPD management, we can pave the way for personalized and comprehensive treatment approaches that integrate both conventional and complementary modalities. Ultimately, this can contribute to improved outcomes, enhanced quality of life, and a more holistic approach to COPD care. Subsequently, in this consider, we explored the impacts of different home grown drugs on asthma and COPD in real-world clinical hone at the Korean Pharmaceutical Clinic to distinguish candidates for novel restorative specialists. We watched the symptomatic criteria utilized by Korean medication specialists to endorse home grown solutions, varieties in endorsed home grown medications, and assorted clinical highlights, counting respiratory side effects, lung work, quality of life, and physical exercises in patients with asthma or COPD. We anticipate that our discoveries will be utilized as a premise to discover an viable home grown pharmaceutical and to create a well-designed clinical trial to affirm the security and adequacy of home grown solutions in obstructive aviation route infections. This imminent observational consider investigated the impacts of home grown solutions in patients with asthma and COPD. The think about was conducted at the Daejeon Korean Pharmaceutical Clinic of Daejeon College between 26 February 2019 and 4 December 2020. A add up to of 24 patients analyzed with asthma or COPD were selected, and 19 completed the ponder. After members were decided to be qualified based on the incorporation and prohibition criteria and deliberately marked a composed assent frame, they were endorsed suitable home grown medications based on design distinguishing proof determination by a proficient clinician of Korean medication. All members were inquired to visit the clinic at slightest each 4 weeks (week 0, week 4, week 8, and week 12) for 12 weeks to get their home grown medications, as well as to assess security and viability endpoints. Amid the think about period, members were permitted to visit the clinic as frequently as they required and get other Korean medication treatment alternatives, such as needle therapy, pharmacoacupuncture, moxibustion, measuring, and physical treatments or Western solutions. All of these concomitant medicines were recorded, and all information were coded privately. Members matured 19 a long time who were analyzed with asthma according to the Worldwide Activity for Asthma (GINA) standard or COPD within the Worldwide Activity for Unremitting Obstructive Lung Malady (GOLD) standard were selected in our ponder. Those who met any of the taking after criteria were avoided: nearness of serious respiratory malady other than asthma or COPD (for case, cystic fibrosis, pneumonia, interstitial lung illness, or lung cancer); history of manhandle or reliance on liquor or other substances; history or nearness of clinically significant cardiovascular, renal, metabolic, hematological, neurological, psychiatric, systemic, or irresistible illness or threatening tumor (but in patients with no prove of tumor repeat for more than 5 a long time after surgery); illness that can influence medicate assimilation or stomach related clutters after related surgery; history of extreme touchiness and sensitivities to research-related drugs; pregnancy or breastfeeding; or patients judged by the agents to be improper for incorporation within the clinical ponder.


  1. VestboJ, HurdSS, Agustí AG etal. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.Am J Respir Crit Care Med.187, 347-365 (2013).
  2. Indexed at, Google Scholar, Crossref

  3. Miller MS, Tilley LP, Smith FW. Cardiopulmonary disease in the geriatric dog and cat. The Veterinary Clinics of North America. J Small Anim Pract.19, 87-102 (1989).
  4. Indexed at, Google Scholar, Crossref

  5. Cheng J, Eroglu A.The Promising Effects of Astaxanthin on Lung Diseases.Adv Nutr.12, 850-864 (2021).
  6. Indexed at, Google Scholar, Crossref

  7. NambiarS, Bong HowS, Gummer J et al. Metabolomics in chronic lung diseases.Respirology.25, 139-148 (2020).
  8. Indexed at, Google Scholar, Crossref

  9. Jiménez-RuizCA, Fagerström KO. Smoking cessation treatment for COPD smokers: the role of counselling. Monaldi Arch Chest Dis.79, 33-37 (2013).
  10. Indexed at, Google Scholar, Crossref

  11. Cheyne L, Irvin-Sellers MJ, WhiteJ.Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. CD009552 (2015).
  12. Indexed at, Google Scholar, Crossref

  13. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380, 2163-2196 (2012).
  14. Indexed at, Google Scholar, Crossref

  15. ZhengY, ZhuJ, LiuY etal. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis.BMJ.363, k4388 (2018).
  16. Indexed at, Google Scholar, Crossref

  17. Szalontai K, Gémes N, Furák J etal. Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer.J Clin Med.10,2889(2021)
  18. Indexed at, Google Scholar, Crossref

  19. VollenweiderDJ, Frei A, Steurer-SteyCA et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. CD010257 (2018).
  20. Indexed at, Google Scholar, Crossref